Opinion|Videos|December 18, 2024
Clinical Insights on Managing Ruxolitinib Cytopenias: Patient-Focused Approach
Author(s)Andrew Kuykendall, MD, Venu Konala, MD
Panelists discuss the patient and disease characteristics influencing the decision to dose-reduce ruxolitinib vs switching therapy. They share their typical sequencing approach after first-line ruxolitinib, including whether a washout period or overlap is required.
Advertisement
Episodes in this series
- Dr Kuykendall to Dr Konala: What patient and/or disease characteristics do you consider when deciding to dose-reduce ruxolitinib vs change therapy? How do you take into account your patient’s preference in this situation?
- Dr Kuykendall: Please share your typical sequencing approach post first-line ruxolitinib. What does the process look like? Does it require a washout period or overlap?
Advertisement
Related to this article
The FDA approved RP1 plus nivolumab in advanced melanoma, granted olomorasib breakthrough status in KRAS G12C+ pancreatic cancer, and more.
Sonrotoclax monotherapy produced durable responses in Chinese patients with relapsed/refractory mantle cell lymphoma.
lan M. Thompson Jr., MD, discusses the potential role of 5-ARIs for the treatment of patients with prostate cancer.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
UCSF Health’s Adam Blaisdell, MD, PhD, has been selected as an IGNITE fellow by the Cancer Research Institute.
BI-1808 combined with pembrolizumab elicited a 24% confirmed overall response rate in heavily pretreated, platinum-resistant recurrent ovarian cancer.
Eric K. Singhi, MD, and Kyle G. Mitchell, MD, MSc, discuss the present and future role of LCT in NSCLC.
Mariana C. Stern, PhD, discusses the biggest gaps identified in the 2026 AACR Disparities Progress Report and what oncologists can do to combat them.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to BI-1808 Plus Pembrolizumab in Ovarian Cancer
2
Exploring the Rationale for 5-Alpha Reductase Inhibitors in Prostate Cancer Prevention and Active Surveillance
3
FDA Grants Accelerated Approval to RP1 Plus Nivolumab for Advanced Melanoma After Anti–PD-1 Therapy
4
The OncFive: Top Oncology Articles for the Week of 8/2
5